Compounds of structure (I):
including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
and R
7
are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
Six new ruthenium complexes bearing a bidentate (κ2O,C)-isopropoxy-indenylidene and PPh3 or PCy3 ligands have been synthesized and characterized by 1H, 13C NMR spectroscopy and X-ray crystallography. Some of these complexes were synthesized in dimethyl carbonate, a green solvent that was recently shown to be suitable for several catalytic transformations including olefin metathesis. The thermal stability
六个新的钌络合物轴承二齿(κ 2 ö,Ç)异丙氧基茚基和PPH 3或PCY 3配体已被合成和表征通过1个H,13 C NMR光谱和X-射线晶体学。这些络合物中的一些是在碳酸二甲酯(一种绿色溶剂)中合成的,碳酸二甲酯最近被证明适用于包括烯烃复分解在内的多种催化转化。含PCy 3的配合物的热稳定性和催化效率已通过一系列测试反应进行了评估。
<scp>Ligand‐Promoted</scp>
, Enantioconvergent Synthesis of Aliphatic Alkanes Bearing Trifluoromethylated Stereocenters via Hydrotrifluoroalkylation of Unactivated Alkenes
作者:Yan He、Kang‐Jie Bian、Bing‐Bing Wu、Peng Liu、Shan‐Xiu Ni、Xi‐Sheng Wang
DOI:10.1002/cjoc.202200142
日期:2022.7
trifluoroalkyl source for inducing effective stereoconvergent differentiation. Leveraging novel design of sterically hindered bisoxazoline ligand and drastic increase of molecular complexity of in situ generated sp3 coupling partner via metal-hydride atom transfer, herein, we report a nickel-catalyzed, highly enantioselective hydrotrifluoroalkylation of unactivatedalkenes for diverse synthesis of enantioenriched
Compounds of structure (I):
including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
The present invention relates to soluble organic compounds, to compositions comprising these compounds, to formulations comprising the compounds or compositions, and to electronic devices.